- Home
- IZM vs INAB Comparison
IZM vs INAB Comparison
Compare IZM & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IZM
- INAB
- Stock Information
- Founded
- IZM 2011
- INAB 2016
- Country
- IZM China
- INAB United States
- Employees
- IZM N/A
- INAB N/A
- Industry
- IZM Consumer Electronics/Video Chains
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- IZM Consumer Discretionary
- INAB Health Care
- Exchange
- IZM Nasdaq
- INAB Nasdaq
- Market Cap
- IZM 21.1M
- INAB 18.8M
- IPO Year
- IZM 2023
- INAB 2021
- Fundamental
- Price
- IZM $1.91
- INAB $0.19
- Analyst Decision
- IZM
- INAB Strong Buy
- Analyst Count
- IZM 0
- INAB 2
- Target Price
- IZM N/A
- INAB $3.60
- AVG Volume (30 Days)
- IZM 42.2K
- INAB 786.0K
- Earning Date
- IZM 04-29-2025
- INAB 05-08-2025
- Dividend Yield
- IZM N/A
- INAB N/A
- EPS Growth
- IZM N/A
- INAB N/A
- EPS
- IZM N/A
- INAB N/A
- Revenue
- IZM $177,933,890.00
- INAB N/A
- Revenue This Year
- IZM N/A
- INAB N/A
- Revenue Next Year
- IZM N/A
- INAB N/A
- P/E Ratio
- IZM N/A
- INAB N/A
- Revenue Growth
- IZM N/A
- INAB N/A
- 52 Week Low
- IZM $1.18
- INAB $0.13
- 52 Week High
- IZM $52.21
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- IZM 63.26
- INAB 49.14
- Support Level
- IZM $1.70
- INAB $0.15
- Resistance Level
- IZM $1.90
- INAB $0.18
- Average True Range (ATR)
- IZM 0.08
- INAB 0.02
- MACD
- IZM 0.00
- INAB 0.01
- Stochastic Oscillator
- IZM 89.66
- INAB 93.22
About IZM ICZOOM Group Inc.
ICZOOM Group Inc is engaged in the sale of electronic component products to customers in China. These products are used by small and medium-sized enterprises (SMEs) in the consumer electronic industry, Internet of Things (IoT), automotive electronics, and industrial control segment. In addition to the sales of electronic component products, also provides services to customers such as temporary warehousing, logistic and shipping, and customs clearance and charges them additional service commission fees. The company earns maximum revenue from sale of electronic components.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.